Origin Capital — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
ViaNautisvianautis.cominNov 2023
ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsCambridge Angels groupOxford Investment Opportunity Network (OION)4BIO CapitalUCB Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.